Under a tenth of individuals that would benefit from obesity jabs such as Wegovy can access them, caution the WHO as it issues its first advice on the drugs.
With in excess of 1,000,000,000 individuals worldwide now classified as obese, it is advocating for broader and more equitable availability to GLP-1 medication.
Per estimates, in excess of 2,000,000,000 could be living with obesity by 2030 unless action is taken.
"Our latest guidance recognises that excess weight is a long-term condition that can be treated with comprehensive and ongoing care," remarked the agency's head Tedros Adhanom Ghebreyesus.
Substantial prices, insufficient output, and supply-chain constraints are major hurdles to widespread availability to the injections that can help people shift considerable weight, says the organization.
Skinny Jab Scarcity
Even in the current best projected outlook, the manufacturing of GLP-1 therapies could only cover about 100 million people – under 10% of those who need them, as stated by the WHO.
The guideline calls on governments and firms to increase availability, via strategies such as voluntary licensing.
A patent on the active ingredient – the core ingredient of a leading brand – is scheduled to end in a number of countries in 2026.
How Obesity Injections Operate
GLP-1 drugs replicate a body's own hormone to reduce digestion speed, suppress the appetite and boost satiety so users consume fewer calories.
People typically start to lose weight in the initial weeks of commencing the weekly injections.
Research points to people may put most of the weight back on after a year of halting the drug, as their normal food cravings return.
To be carrying excess weight elevates your risk for developing health problems, including type 2 diabetes, heart disease, brain attack, and some malignancies.
Excess weight affects people in countries worldwide and was linked to over three and a half million fatalities worldwide in 2024, as per the WHO.
